New Insights into the In Silico Prediction of HIV Protease Resistance to Nelfinavir

The Human Immunodeficiency Virus type 1 protease enzyme (HIV-1 PR) is one of the most important targets of antiretroviral therapy used in the treatment of AIDS patients. The success of protease-inhibitors (PIs), however, is often limited by the emergence of protease mutations that can confer resistance to a specific drug, or even to multiple PIs. In the present study, we used bioinformatics tools to evaluate the impact of the unusual mutations D30V and V32E over the dynamics of the PR-Nelfinavir complex, considering that codons involved in these mutations were previously related to major drug resistance to Nelfinavir. Both studied mutations presented structural features that indicate resistance to Nelfinavir, each one with a different impact over the interaction with the drug. The D30V mutation triggered a subtle change in the PR structure, which was also observed for the well-known Nelfinavir resistance mutation D30N, while the V32E exchange presented a much more dramatic impact over the PR flap dynamics. Moreover, our in silico approach was also able to describe different binding modes of the drug when bound to different proteases, identifying specific features of HIV-1 subtype B and subtype C proteases.

[1]  P. Pascutti,et al.  Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations. , 2010, Journal of molecular graphics & modelling.

[2]  Lubomír Rulísek,et al.  Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants. , 2007, Journal of molecular biology.

[3]  Masayuki Hata,et al.  Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease. , 2007, Journal of molecular biology.

[4]  Jung-Hsin Lin,et al.  Restrained molecular dynamics simulations of HIV‐1 protease: The first step in validating a new target for drug design , 2006, Biopolymers.

[5]  R. Shafer,et al.  N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. , 2006, AIDS research and human retroviruses.

[6]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[7]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[8]  T. Meek,et al.  Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. , 1991, Biochemistry.

[9]  An insight into the opening path to semi-open conformation of HIV-1 protease by molecular dynamics simulation , 2010 .

[10]  M. Soares,et al.  The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors. , 2011, Memorias do Instituto Oswaldo Cruz.

[11]  R. Shafer,et al.  Update of the drug resistance mutations in HIV-1: March 2013. , 2013, Topics in antiviral medicine.

[12]  P A Fernandes,et al.  Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead. , 2007, Journal of molecular graphics & modelling.

[13]  A. Singla,et al.  Drug resistance-associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India. , 2008, AIDS research and human retroviruses.

[14]  S. Carr,et al.  Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange. , 1991, Biochemistry.

[15]  Vassilios Ioannidis,et al.  ExPASy: SIB bioinformatics resource portal , 2012, Nucleic Acids Res..

[16]  J. Mccammon,et al.  HIV‐1 protease molecular dynamics of a wild‐type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs , 2004, Protein science : a publication of the Protein Society.

[17]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir , 2011, PLoS Comput. Biol..

[18]  R. Ambinder,et al.  Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention , 2013, Current opinion in oncology.

[19]  R. Shafer,et al.  HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance , 2010, Antimicrobial Agents and Chemotherapy.

[20]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[21]  J. Chies,et al.  Co‐circulation HIV‐1 subtypes B, C, and CRF31_BC in a drug‐naïve population from Southernmost Brazil: Analysis of primary resistance mutations , 2011, Journal of medical virology.

[22]  Qinggang Zhang,et al.  Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: Free energy calculation and molecular dynamic simulation , 2010, Journal of molecular modeling.

[23]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[24]  M. Soliman,et al.  Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance , 2013, Journal of biomolecular structure & dynamics.

[25]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[26]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[27]  Parimal Kar,et al.  Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir , 2012, Journal of Computer-Aided Molecular Design.

[28]  Irene T Weber,et al.  Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. , 2008, Accounts of chemical research.

[29]  Ursula Rothlisberger,et al.  Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.

[30]  Michele Parrinello,et al.  Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. , 2002, Journal of molecular biology.

[31]  P. Pascutti,et al.  Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia , 2007, Cell Biochemistry and Biophysics.

[32]  D. M. F. Aalten,et al.  PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules , 1996, J. Comput. Aided Mol. Des..

[33]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[34]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[35]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using Modeller , 2006, Current protocols in bioinformatics.